Jade Jones, MD
Medical Oncology · Atlanta, GANPI 1487064432
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,660 of the $8,197 with a category attached, or 69.1%. 7 manufacturers reported payments, led by Gilead at 55.6% of the total. Reporting peaked in 2024 at $7,929 and has fallen 98.5% since, to $116 in 2025. That places this record below the midpoint for medical oncology clinicians in GA, where the typical reported total is $5,509.
Across 22 payments — averaging $372.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$5K
- Tersera Therapeutics LLC$3K
- Johnson & Johnson Surgical Vision, Inc.$97
- Genentech USA, Inc.$94
- Adlon Therapeutics L.p.$43
- Eisai Inc.$17
- plus $12 from 1 others
What the payments were for
- Consulting fees$5,66069%
- Travel & lodging$1,92423%
- Food & beverage$6127%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 9 | $4,558 |
| Tersera Therapeutics LLC | 6 | $3,376 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $97 |
| Genentech USA, Inc. | 2 | $94 |
| Adlon Therapeutics L.p. | 2 | $43 |
| Eisai Inc. | 1 | $17 |
| Bristol Myers Squibb | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,197 in reported general payments places this provider in the 50th percentile of 68 medical oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 34 | $514,121 |
| IbrancePalbociclib | 11 | $173,575 |
| Exemestane | 63 | $7,375 |
| Letrozole | 40 | $893 |
| Anastrozole | 58 | $820 |
| Prochlorperazine Maleate | 26 | $271 |
| Ondansetron Hcl | 17 | $191 |
| Dexamethasone | 28 | $151 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Atlanta
- Nabil SabaAtlanta$225K
- Suresh RamalingamAtlanta$75K
- Jonathan KaufmanAtlanta$73K
- Ragini KudchadkarAtlanta$69K
- Nisha JosephAtlanta$50K
- Eyal MeiriAtlanta$39K
- Erin DunbarAtlanta$35K
- Olumide GbolahanAtlanta$32K
- Bradley CarthonAtlanta$31K
- Joseph MaakaronAtlanta$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.